JP2010530403A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530403A5
JP2010530403A5 JP2010512761A JP2010512761A JP2010530403A5 JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5 JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010512761 A JP2010512761 A JP 2010512761A JP 2010530403 A5 JP2010530403 A5 JP 2010530403A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
alkyl
carboaryl
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010512761A
Other languages
English (en)
Japanese (ja)
Other versions
JP5725605B2 (ja
JP2010530403A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/002066 external-priority patent/WO2008155533A2/en
Publication of JP2010530403A publication Critical patent/JP2010530403A/ja
Publication of JP2010530403A5 publication Critical patent/JP2010530403A5/ja
Application granted granted Critical
Publication of JP5725605B2 publication Critical patent/JP5725605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010512761A 2007-06-19 2008-06-17 軽度認知障害を処置するためのフェノチアジン化合物 Active JP5725605B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (3)

Publication Number Publication Date
JP2010530403A JP2010530403A (ja) 2010-09-09
JP2010530403A5 true JP2010530403A5 (enExample) 2011-08-04
JP5725605B2 JP5725605B2 (ja) 2015-05-27

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512761A Active JP5725605B2 (ja) 2007-06-19 2008-06-17 軽度認知障害を処置するためのフェノチアジン化合物

Country Status (16)

Country Link
US (1) US9211294B2 (enExample)
EP (1) EP2167095B1 (enExample)
JP (1) JP5725605B2 (enExample)
CN (1) CN101820884B (enExample)
AU (1) AU2008265045B2 (enExample)
BR (1) BRPI0813670A2 (enExample)
CA (1) CA2690746C (enExample)
DK (1) DK2167095T3 (enExample)
ES (1) ES2739546T3 (enExample)
HR (1) HRP20191513T1 (enExample)
HU (1) HUE045460T2 (enExample)
MY (1) MY177001A (enExample)
PL (1) PL2167095T3 (enExample)
PT (1) PT2167095T (enExample)
SI (1) SI2167095T1 (enExample)
WO (1) WO2008155533A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
CA2701075C (en) * 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5868955B2 (ja) 2010-04-30 2016-02-24 プロセッタ アンチバイラル インコーポレイテッド 抗ウイルス化合物
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
EP2699241B1 (en) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antiviral compounds
US9523045B2 (en) * 2013-01-30 2016-12-20 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
US10472340B2 (en) * 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
KR20250154422A (ko) 2023-03-03 2025-10-28 타우알엑스 쎄라퓨틱스 매니지먼트 리미티드 미세혈관 뇌질환 치료를 위한 디아미노페노티아진

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) * 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) * 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
EP1617844A4 (en) * 2003-04-03 2009-07-22 Prana Biotechnology Ltd TREATMENT OF NEUROLOGICAL DISEASES
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
SI2322517T1 (sl) * 2004-09-23 2019-06-28 Wista Laboratories Ltd. Postopki za kemijsko sintezo in čiščenje diaminofenotiazinijevih spojin, vključno metiltioninijevega klorida (MTC)
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
SI2004155T1 (en) * 2006-03-29 2018-05-31 Wista Laboratories Ltd. Inhibitors of protein aggregation
ES2349322T7 (es) * 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) * 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
MY148145A (en) * 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds

Similar Documents

Publication Publication Date Title
JP2010530403A5 (enExample)
JP2009531404A5 (enExample)
JP7407740B2 (ja) Tlr7/tlr8阻害剤の結晶形態
JP2019104748A5 (enExample)
JP2005533868A5 (enExample)
AU2012274160B2 (en) Deuterium-enriched 4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo- N-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP2012507522A5 (enExample)
TW200529850A (en) Methods of preparing aripiprazole crystalline forms
JP2009528271A5 (enExample)
JP2009526034A5 (enExample)
JP6830888B2 (ja) Jak阻害剤の硫酸水素塩の結晶形およびその製造方法
JP2014511898A5 (enExample)
JP2015508092A5 (enExample)
JP2010155827A5 (enExample)
JP6203841B2 (ja) カルバメート/尿素誘導体
JP2009506014A5 (enExample)
JP2010521516A5 (enExample)
JP2025131661A (ja) 2-(5-(4-(2-モルホリノエトキシ)フェニル)ピリジン-2-イル)-n-ベンジルアセトアミドの固体形態
ES2907590T3 (es) Método para preparar un derivado heterocíclico
JP2018529643A (ja) ユビキチン化−プロテアソーム系に関連する化合物および薬学的組成物
JP2007538031A5 (enExample)
JP5710490B2 (ja) (r)−5−((e)−2−(ピロリジン−3−イルビニル)ピリミジンの合成および新規の塩形態
TW201018668A (en) Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
JP2009525292A5 (enExample)
JP2006511498A5 (enExample)